Pfizer Raises Forecast on Momentum With New Products

What happened

Pfizer raised its full-year outlook, forecasting sales of $62 billion to $64 billion and adjusted earnings per share of $2.95 to $3.05. Third-quarter sales were $16.58 billion and profit was $3.24 billion, while newly launched and acquired products grew 7%.

Confirmed

Global impact / market context

Stronger sales from new and acquired products are replacing falling Covid-19 revenue, which supports Pfizer's profit and cash. A higher forecast signals management expects that shift to continue, which matters for investors judging whether earnings can keep growing without pandemic-era products.

Analyst inference

Pfizer's results beat analyst sales and earnings estimates, and its new guidance midpoint roughly matches expected sales but slightly exceeds expected earnings. That suggests cost control and product mix are helping, even as Covid-19 vaccine and treatment sales decline and investors weigh the company's post-pandemic growth path.

Analyst inference

What to watch

1. Watch whether sales of recently launched and acquired products keep growing 7% or faster, offsetting further declines in Covid-19 vaccine and treatment revenue. Confirmed
2. Track Pfizer's spending on research and acquisitions, since buying or developing new products is how it aims to replace lost Covid-19 revenue. Proposed
3. Cecile Guegan becomes chief financial officer on Nov. 1, so her guidance on costs, cash and capital spending may shape investor expectations. Analyst inference

Evidence

• Original source link unavailable